KR20010018321A - Composition of healthfood for Rheumatoid arthritis - Google Patents

Composition of healthfood for Rheumatoid arthritis Download PDF

Info

Publication number
KR20010018321A
KR20010018321A KR1019990034223A KR19990034223A KR20010018321A KR 20010018321 A KR20010018321 A KR 20010018321A KR 1019990034223 A KR1019990034223 A KR 1019990034223A KR 19990034223 A KR19990034223 A KR 19990034223A KR 20010018321 A KR20010018321 A KR 20010018321A
Authority
KR
South Korea
Prior art keywords
glucosamine
health food
chondroitin sulfate
chitooligosaccharide
food composition
Prior art date
Application number
KR1019990034223A
Other languages
Korean (ko)
Inventor
박명환
Original Assignee
박명환
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박명환 filed Critical 박명환
Priority to KR1019990034223A priority Critical patent/KR20010018321A/en
Publication of KR20010018321A publication Critical patent/KR20010018321A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/28—Oligosaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A23V2250/308—Glucosamine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/50—Polysaccharides, gums
    • A23V2250/51—Polysaccharide
    • A23V2250/511—Chitin, chitosan

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE: A health food composition for articular rheumatism is provided to prevent destruction of cartilage and bone by mixing chitooligosaccharide containing glucosamine 5-80% and chondroitin sulfate. CONSTITUTION: The health food composition for articular rheumatism contains 5-90 weight parts of chitooligosaccharide having a glucosamine monomer content of 5-80% and 5-90 weight parts of chondroitin sulfate derived from shark cartilage or cow cartilage. The health food composition includes vitamin A, vitamin B, vitamin C, vitamin E, niacin amide, pantothenic acid, calcium, iron, zinc and selenium as supplementary substances. The composition is manufactured as a tablet, a capsule, a pill, a granular or liquid type. The liquid type of the composition has a natural flavor like Japanese apricot, lemon, pineapple and herb, a natural coloring matter like chlorophyllin and flavonoid, a sweetener like fructose, honey, sugar alcohol and sugar, or an acidic agent like citrate and sodium citrate.

Description

류마티스 관절염 환자를 위한 건강식품 조성물{Composition of healthfood for Rheumatoid arthritis}Composition of healthfood for Rheumatoid arthritis}

본 발명은 글루코사민을 함유하는 키토올리고당과 황산콘드로이친을 함유하는 것을 특징으로하는 류마티스 관절염 치료효과가 있는 건강식품 조성물에 관한 것이다.The present invention relates to a health food composition having a therapeutic effect on rheumatoid arthritis, which comprises glucosamine-containing chitooligosaccharide and chondroitin sulfate.

류마티스 관절염은 관절 및 관절 관련 조직의 통증, 부종, 뻣뻣한 증세(Stiffness)로 대표되는 만성적 염증 질환으로 성인 인구의 1% 정도가 환자이며 여성이 남성보다 2-3배 더 많이 발생하는 질환이다. 초기 증상 치료용 약물로 비스테로이드성 소염진통제들이 많이 개발되어 있고, 진행성 악화 증상 병태 개선약으로는 스테로이드 제제, 히드록시클로로퀸(Hydroxy chloroquine), 금, 메토트렉세이트(Methotrexate), 슬파살라진(Sulfasulazine), 아자치오프린(Azathioprine), 페니실라민, 싸이크로스포린 A등이 개발되어 있다.Rheumatoid arthritis is a chronic inflammatory disease represented by pain, swelling, and stiffness in joints and joint tissues, affecting about 1% of the adult population and 2-3 times more women than men. Many nonsteroidal anti-inflammatory drugs have been developed for the treatment of early symptoms, and steroid preparations, hydroxychloroquine, gold, methotrexate, sulfasulazine, Azathioprine, penicillamine, and cyclosporin A have been developed.

이 약물들은 증상 완화등의 효과는 있으나 위장장애, 신장장애, 혈소판 응집장애, 과민 반응등 부작용이 있어 특히 병태개선약들은 의사의 엄격한 관리감독하에 투약되어야 하는 불편함이 많다.These drugs are effective in relieving symptoms, but have side effects such as gastrointestinal disorders, kidney disorders, platelet aggregation disorders, and hypersensitivity reactions. In particular, pathologic drugs need to be administered under the strict supervision of a doctor.

류마티스 관절염이 발생하는 병인은 관절 및 관절막에 각종 유해 효소, 유해 세포, 유해한 싸이토카인등의 작용으로 활막이 부어 오르고 열을 내고 통증을 일으켜 증식하게 됩니다. 이 활막에서 윤활액(활액)이 생성되는 데 관절염 환자는 변질된 윤활액을 만들어 냅니다. 이 변질된 윤활액 중에는 연골과 뼈몸체까지 녹여버리는 물질들이 가득차 있습니다. 지금까지 개발된 약물들 대부분은 증상에 대한 대증요법제이며, 특히 연골 파괴, 뼈 파괴를 저지할 수 있는 효능은 미미하기때문에 뼈 파괴를 막아주는 약물이나 건강식품의 출현이 절실히 요청되는 상황이다.The etiology of rheumatoid arthritis is caused by swelling of the synovial membrane, heat and pain caused by the action of various harmful enzymes, harmful cells and harmful cytokines on the joints and joint membranes. The synovial fluid (synovial fluid) is produced in the synovial membrane, and arthritis patients produce a corrupted lubricant. This altered lubricant is filled with substances that dissolve cartilage and bones. Most of the drugs developed so far are symptomatic treatments for symptoms, and in particular, the effects of inhibiting cartilage destruction and bone destruction are insignificant, and thus there is an urgent need for the emergence of drugs or health foods that prevent bone destruction.

본 발명자는 부작용은 없으면서 연골 파괴, 뼈 파괴를 저지할 수 있는 효능을 갖고 류마티스 관절염 치료 효과가 있는 성분을 찾고자 많은 연구를 수행한 결과 글루코사민을 함유하는 키토올리고당과 황산콘드로이친을 혼합한 조성물이 관절염 치료 효과가 우수함을 확인하여 본 발명을 완성하였다.The present inventors conducted a number of studies to find a component that has the effect of inhibiting cartilage destruction and bone destruction without side effects, and is effective in treating rheumatoid arthritis, and as a result, a composition comprising glucosamine-containing chitooligosaccharide and chondroitin sulfate is treated for arthritis. It confirmed that the effect is excellent to complete the present invention.

따라서 본 발명의 목적은 글루코사민을 함유하는 키토올리고당과 황산콘드로이친을 함유함을 특징으로 하는 류마치스 관절염 치료 효과가 있는 건강식품 조성물을 제공하는 데 있다. 또 다른 목적은 글루코사민을 함유하는 키토올리고당과 황산콘드로이친을 함유함을 특징으로 하는 정제, 캡슐제, 환제, 과립제, 액제의 제형을 제공하는 데 있다.Therefore, an object of the present invention is to provide a health food composition having a therapeutic effect of rheumatoid arthritis, characterized by containing glucosamine-containing chitooligosaccharide and chondroitin sulfate. Another object is to provide a formulation of tablets, capsules, pills, granules, liquids, characterized in that it contains glucosamine-containing chitooligosaccharide and chondroitin sulfate.

본 발명은 글루코사민을 함유하는 키토오리고당과 황산콘드로이친을 함유함을 특징으로 하는 류마티스관절염 치료 효과를 갖는 건강식품 조성물에 관한 것이다.The present invention relates to a health food composition having a therapeutic effect of rheumatoid arthritis, which comprises glucosamine-containing chitooligosaccharide and chondroitin sulfate.

글루코사민은 세포막 및 연골 구성 성분으로서 관절염 치유, 류마티스 신경통 치유 효능을 갖고 있으며, 의약품 원료로 허가되어 있고 미국등에서는 식품 원료로 사용 중이지만 대한민국에서는 건강식품 소재로 허가 되지 않아 식품에 사용할 수 없다. 또한 글루코사민의 제조 원료로 사용되는 키토산 또는 키토올리고당(2당류 이상 함유)은 건강식품 원료로 허가되어 있으나 사람의 몸속에서는 단당류인 글루코사민으로 소화분해되지 않으므로 연골의 구성 성분으로 이용될 수 없고 류마티스 치료 효과를 기대할 수 도 없다. 본 발명은 키토올리고당을 제조할 때 글루코사민 단량체를 만들 수 있는 효소를 사용함으로써 글루코사민이 5-80% 함유된 키토올리고당이 제조 가능함으로 이런 글루코사민을 함유하는 키토올리고당을 사용함으로써 건강식품의 조건을 만족시키면서 류마티스 관절염 치료 효과를 발휘할 수 있는 조성물을 발명하게 되었다.Glucosamine is a cell membrane and cartilage component that has the effect of healing arthritis and rheumatoid neuralgia.It is licensed as a pharmaceutical ingredient and used as a food ingredient in the United States, but it is not approved as a health food ingredient in Korea and cannot be used in food. In addition, chitosan or chitooligosaccharide (containing more than 2 sugars), which is used as a raw material for glucosamine, is licensed as a health food raw material, but it cannot be used as a component of cartilage because it is not digested into glucosamine, a monosaccharide in the human body, and has a therapeutic effect on rheumatism. Can not expect. The present invention is to prepare a glucosamine monomer by using an enzyme that can make a glucosamine monomer when preparing the chito oligosaccharides, so that can satisfy the conditions of health food by using a chito oligosaccharides containing glucosamine. The invention has been invented a composition that can exert the therapeutic effect of rheumatoid arthritis.

황산콘드로이친은 인체에서 뼈, 각막, 혈관벽등의 결합조직에 많이 함유되어 있으며 시력보호, 야맹증, 안구건조증, 신경통 관절염 치료 효과, 콜레스테롤 강하 작용, 상처치유, 간장보호 기능을 갖는 소재로 개발되어 건강 식품으로 활용되고 있다.Chondroitin sulfate is contained in the connective tissues such as bone, cornea, and blood vessel wall in the human body, and it is developed as a material that has the function of protecting eyesight, night blindness, dry eye, neuralgia arthritis, cholesterol lowering effect, wound healing, and hepatoprotective function. It is used as.

본 발명에서는 글루코사민이 함유된 키토올리고당에 황산콘드로이친을 혼합조성물로 사용함으로써 단독으로 사용할 때보다 현저한 류마티스 관절염 치료 효과가 확인되었으므로 본 발명은 신규한 것이다.In the present invention, by using chondroitin sulfate in the glucosamine-containing chitooligosaccharide as a mixed composition, a significant effect of treating rheumatoid arthritis was confirmed than when used alone, and the present invention is novel.

이하 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.

본 발명은 글루코사민을 함유하는 키토올리고당과 황산콘드로이친을 함유함을 특징으로하는 건강식품 조성물에 관한 것이며 류마티스 관절염 치료 효과를 나타낸다.The present invention relates to a health food composition characterized by containing glucosamine-containing chitooligosaccharide and chondroitin sulfate and exhibits a therapeutic effect on rheumatoid arthritis.

글루코사민을 함유하는 키토올리고당은 글루코사민 단량체의 함량이 5-80%인 것을 사용할 수 있고 5-90중량부 사용한다.Glucosamine-containing chitooligosaccharide can be used that the content of the glucosamine monomer is 5-80% and used 5-90 parts by weight.

황산콘드로이친은 상어 연골, 소 연골을 원료로 하여 제조되어 시판 중인 것을 구입하여 5-90중량부 사용한다.Chondroitin sulfate is manufactured from shark cartilage and bovine cartilage as raw materials, and is commercially available and used 5-90 parts by weight.

본 발명은 보조 성분으로 비타민 A, B군, C, E, 니아신아미드, 판토텐산과 미네랄로 칼슘, 철, 아연, 셀레니움등을 함께 사용할 수 있다.The present invention can be used together with vitamins A, B, C, E, niacinamide, pantothenic acid and calcium, iron, zinc, selenium, and the like as auxiliary components.

본 발명의 제형은 통상적인 방법에 따라 정제, 캡슐제, 환제, 과립제, 액제로 제조될 수 있다.Formulations of the present invention may be prepared in tablets, capsules, pills, granules, solutions according to conventional methods.

이때 액제등과 같은 제형으로 제조할 경우 미각을 돋구기 위하여 매실향, 레몬향, 파인애플향 또는 허브향과 같은 천연향료나 천연과즙, 클로르필린(chlorphyllin), 플라보노이드(flavonoid) 등의 천연색소 및 감미성분인 과당, 벌꿀, 당알콜, 설탕등과 구연산, 구연산 나트륨과 같은 산미제를 혼합하여 사용할 수 있다.At this time, in order to enhance the taste, natural flavors such as plum flavor, lemon flavor, pineapple flavor, or herbal flavor, natural fruit juice, chlorphyllin, flavonoid, flavonoid, etc. Phosphorous fructose, honey, sugar alcohol, sugar, etc. may be mixed with an acidulant such as citric acid and sodium citrate.

이하 본 발명을 실시예에 의하여 상세히 설명하고자 하며 본 발명이 다음 실시예에 의하여 한정되는 것은 아니다Hereinafter, the present invention will be described in detail by way of examples, and the present invention is not limited by the following examples.

[ 실시예 ]EXAMPLE

[실시예 1] 정제Example 1 Tablet

글루코사민이 40% 함유된 키토올리고당 50 g, 소 연골 유래 황산콘드로이친 분말 5 g을 상법에 따라 직타하여 500 mg 정제 15O정을 제조하였다.50 g of chitooligosaccharide containing 40% of glucosamine and 5 g of chondroitin sulfate derived from bovine cartilage were directly burned according to a conventional method to prepare 500 mg tablet 15O tablets.

[실시예 2] 과립제Example 2 Granules

글루코사민 40% 함유된 키토올리고당 50 g, 상어 연골 유래 황산콘드로이친 분말 50 g, 카르복시메틸 셀룰로오스 칼슘 10 g, 카르복시메틸 셀룰로오스 5 g, 결정셀룰로오스 50 g을 잘 혼합하여 통상의 방법에 따라 과립을 제조하였다.50 g of chitooligosaccharide containing 40% of glucosamine, 50 g of shark cartilage-derived chondroitin sulfate, 10 g of carboxymethyl cellulose calcium, 5 g of carboxymethyl cellulose, and 50 g of crystal cellulose were mixed to prepare granules according to a conventional method.

[실시예 3] 환제Example 3 Pill

글루코사민이 40%함유된 키토올리고당 5O g, 소 연골 유래 황산콘드로이친 분말 50 g,에 옥수수 전분 50 g, 벌꿀 20 g을 잘 혼합하여 통상의 방법에 따라 1환이 500 mg인 환제를 제조하였다.50 g of chitooligosaccharide containing 40% glucosamine, 50 g of bovine cartilage-derived chondroitin sulfate, 50 g of corn starch, and 20 g of honey were mixed to prepare a pill having 500 mg of one ring according to a conventional method.

[실시예4] 캡슐제Example 4 Capsule

글루코사민이 55% 함유된 키토올리고당 30 g, 소 연골 유래 황산콘드로이친 분말 25 g, 결정 셀룰로오스 15 g을 잘 혼합하고 통상의 방법에 따라 한 캡슐당 500 mg 씩 충전한 캡슐제를 제조하였다.30 g of chitooligosaccharide containing 55% glucosamine, 25 g of bovine cartilage-derived chondroitin sulfate powder, and 15 g of crystalline cellulose were mixed well, and a capsule filled with 500 mg per capsule was prepared according to a conventional method.

[실시예 5] 연질 캡슐제Example 5 Soft Capsule

글루코사민이 40% 함유된 키토올리고당 300 g, 소 연골 유래 황산콘드로이친 분말 200 g, 대두유 480 g, 백납 20 g을 잘 혼합하고 통상의 방법에 따라 젤라틴 연질 캡슐에 내용물 500 mg의 연질 캡슐을 제조하였다.300 g of chitooligosaccharides containing 40% of glucosamine, 200 g of bovine cartilage-derived chondroitin sulfate powder, 480 g of soybean oil, and 20 g of white lead were mixed well, and a soft capsule having a content of 500 mg was prepared in a gelatin soft capsule according to a conventional method.

[실시예 6] 액제Example 6 Liquid

글루코사민 60 % 함유된 키토올리고당 50 g, 소 연골 유래 황산콘드로이친 분말 15g, 카르복시메틸 셀룰로오스 나트륨 3 g, 설탕 2 g, 스테비오사이드 100 mg, 구연산 1 g, 파인애플향 30 mg에 정제수를 가하여 가용화하고 1000 ml의 액제를 제조하였다.50 g of chitooligosaccharide containing 60% glucosamine, 15 g of bovine cartilage-derived chondroitin sulfate, 3 g of carboxymethyl cellulose, 2 g of sugar, 100 mg of stevioside, 1 g of citric acid, and 30 mg of pineapple flavor, solubilized by adding purified water and 1000 ml Was prepared.

[참고예 1]Reference Example 1

글루코사민이 40% 함유된 키토올리고당 50 g을 직타하여 1정당 500 mg의 정제를 제조하였다.A tablet of 500 mg per tablet was prepared by directly hitting 50 g of chitooligosaccharide containing 40% glucosamine.

[참고예 2]Reference Example 2

소 연골 유래 황산콘드로이친 분말 25 g을 직타하여 1정당 500 mg의 정제를 제조하였다.500 mg tablets per tablet were prepared by direct hitting 25 g of bovine cartilage-derived chondroitin sulfate powder.

[실험예 1]Experimental Example 1

생물약과학 실험강좌 제 12권 염증과 알레르기 (광천 서점, 동경)에 수재된 Adjuvant관절염 모델에 의해 류마치스관절염에 대한 약효를 평가하였다.The efficacy of Rheumatoid Arthritis was evaluated by the Adjuvant Arthritis Model, which was published in Biopharmaceutical Experiments, Volume 12.

체중 200-220 g의 Lewis 랫트 32 마리를 4군으로 나누고, 제 1군에는 1%카르복시메틸 셀룰로오스 나트륨 수용액 (CMC-Na); 대조군, 제 2군에는 참고예1의 시료를 1% CMC-Na 수용액에 500 mg/ml의 농도로 녹인 것을, 제 3군에는 참고예2의 시료를 1%CMC-Na 수용액에 250 mg/ml 농도로 녹인 것을, 제 4군에는 실시예1의 시료를 1%CMC-Na 수용액에 750 mg/ml 농도로 녹인 것을 실험 제1일부터 18일간 매일 1회씩 200 mg 체중당 500 ml씩을 경구투여 하였다.32 Lewis rats weighing 200-220 g were divided into four groups, the first group containing 1% aqueous carboxymethyl cellulose solution (CMC-Na); In the control and the second group, the sample of Reference Example 1 was dissolved at a concentration of 500 mg / ml in 1% CMC-Na aqueous solution. In the fourth group, the sample of Example 1 was dissolved at a concentration of 750 mg / ml in a 1% CMC-Na aqueous solution at a concentration of 750 mg / ml, orally administered 500 ml per 200 mg body weight once daily for 18 days. .

실험 제1일에 전 실험군의 랫트 좌측 뒷다리발바닥에 Ajuvant를 주사하였다.On the first day of the experiment, Ajuvant was injected into the bottom of the left hind paw of rats of the entire experimental group.

제18일 최후 시료 투여하고 2시간 후에 좌측뒷다리 발바닥 체적을 측정하고, 혈액을 채취하여 적혈구 침강 속도를 측정하여 그 결과를 표1과 표2에 나타내었다.2 hours after the last day of the 18 days of sample administration, the left hind paw volume was measured, blood was collected, and the erythrocyte sedimentation rate was measured. The results are shown in Tables 1 and 2.

상기 실험예에 나타낸 바와 같이 본 발명의 조성물은 양성대조군으로 사용한 글루코사민 함유 키토올리고당, 소 연골 유래 황산콘드로이친의 류마티스 관절염 억제 효과(족부 체적 증가율) 및 임상검사에서 빈용하는 지표인 적혈구 침강속도 증가 억제효과가 탁월하였다. 두가지 성분을 혼합함으로써 상승적 효과를 나타내는 것으로 사료된다. 또한 본 발명의 조성물은 건강식품으로 사용하였거나 또는 그것으로부터 유래하였으므로 매우 안전하다.As shown in the experimental example, the composition of the present invention is a glucosamine-containing chitooligosaccharide, bovine cartilage-derived chondroitin inhibitory effect on the rheumatoid arthritis (foot volume increase rate) and an increase in the erythrocyte sedimentation rate which is a poor index in clinical examination. Was excellent. It is believed that the mixing of the two components has a synergistic effect. In addition, the composition of the present invention is very safe because it is used or derived from health food.

Claims (5)

활성 성분으로 글루코사민을 함유하는 키토올리고당 및 황산콘드로이친을 함유함을 특징으로 하고 류마티스 관절염 치료 효과가 있는 건강식품 조성물.A health food composition comprising chitooligosaccharides containing glucosamine and chondroitin sulfate as active ingredients and having a therapeutic effect on rheumatoid arthritis. 제1항에 있어서 글루코사민을 함유하는 키토올리고당은 글루코사민을 5-80% 함유함을 특징으로 하는 건강식품 조성물The health food composition according to claim 1, wherein the chitooligosaccharide containing glucosamine contains 5-80% of glucosamine. 제1항에 있어서 황산콘드로이친은 상어 연골 유래품 또는 소 연골 유래품을 사용하는 것을 특징으로 하는 건강식품조성물.The health food composition according to claim 1, wherein the chondroitin sulfate is a shark cartilage derivative or a bovine cartilage derivative. 제1항에 있어서 글루코사민을 함유하는 키토올리고당을 5-90중량부와 황산콘드로이친 5-90중량부를 함유함을 특징으로 하는 건강식품 조성물.The health food composition according to claim 1, comprising 5-90 parts by weight of glucosamine-containing chitooligosaccharide and 5-90 parts by weight of chondroitin sulfate. 제1항에 있어서 제형은 정제, 캡슐제, 환제, 과립제, 액제인 것을 특징으로 하는 건강식품 조성물.The health food composition of claim 1, wherein the formulation is a tablet, capsule, pill, granule, liquid.
KR1019990034223A 1999-08-18 1999-08-18 Composition of healthfood for Rheumatoid arthritis KR20010018321A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019990034223A KR20010018321A (en) 1999-08-18 1999-08-18 Composition of healthfood for Rheumatoid arthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019990034223A KR20010018321A (en) 1999-08-18 1999-08-18 Composition of healthfood for Rheumatoid arthritis

Publications (1)

Publication Number Publication Date
KR20010018321A true KR20010018321A (en) 2001-03-05

Family

ID=19607750

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019990034223A KR20010018321A (en) 1999-08-18 1999-08-18 Composition of healthfood for Rheumatoid arthritis

Country Status (1)

Country Link
KR (1) KR20010018321A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100450016B1 (en) * 2001-07-03 2004-09-22 이순용 Chitin chitosan phill
KR100656571B1 (en) * 2004-06-16 2006-12-13 비타민하우스알앤비티(주) Composition for preventation and treatment of degenerative arthritis
CN1314361C (en) * 2003-04-02 2007-05-09 李安虎 Joint healthy beverage or food and preparation thereof
WO2009007660A1 (en) 2007-07-04 2009-01-15 Mathieu Borge Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation
RU2723584C1 (en) * 2019-10-08 2020-06-16 Игорь Витальевич Слепцов Composition based on collagen from connective tissue of yakut horse and calcium gluconate

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100450016B1 (en) * 2001-07-03 2004-09-22 이순용 Chitin chitosan phill
CN1314361C (en) * 2003-04-02 2007-05-09 李安虎 Joint healthy beverage or food and preparation thereof
KR100656571B1 (en) * 2004-06-16 2006-12-13 비타민하우스알앤비티(주) Composition for preventation and treatment of degenerative arthritis
WO2009007660A1 (en) 2007-07-04 2009-01-15 Mathieu Borge Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation
RU2723584C1 (en) * 2019-10-08 2020-06-16 Игорь Витальевич Слепцов Composition based on collagen from connective tissue of yakut horse and calcium gluconate

Similar Documents

Publication Publication Date Title
RU2533273C2 (en) Compositions with rose hip extracts and method for preparing rose hip extracts
DE69931907T2 (en) HAGA BUTTER COMPOSITIONS AS AN ANTI-INFLAMMABLE NATURAL MEDICAMENT TO FACILITATE / REDUCE SYMPTOMS RELATING TO INFLAMMATION AND ARTHRITIS
US20080044493A1 (en) Agent For Ameliorating The Maximum Passage Time Through Digestive Tract, Agent For Ameliorating Passage Time Through Digestive Tract And Preventive For Colon Cancer
RU2349336C2 (en) Compositions for arthritis state treatment
US5145678A (en) Method of reducing blood serum cholesterol
ES2335876T3 (en) PHARMACEUTICAL COMPOSITION INCLUDED BY A LIPASE AND GLUCOMANAN INHIBITOR.
CN102014893A (en) Polyphenols for the treatment of cartilage disorders
JP5204578B2 (en) Joint pain improving composition, joint pain improving agent, or food
KR20010018321A (en) Composition of healthfood for Rheumatoid arthritis
KR101293645B1 (en) Phamaceutical composition for prevention or treatment of nephritis
KR20010046562A (en) Composition for treatment of osteoarthritis
JPH11255656A (en) Therapeutic composition for atopic dermatitis
KR101237215B1 (en) Phamaceutical composition for prevention or treatment of enteritis
US6793935B2 (en) Mineral supplement
JP2009120502A (en) Chitosan-containing composition
CN116348104A (en) Compositions and methods for cartilage degeneration using a combination of oleuropein and quercetin
EP1175906B1 (en) Blood flow improvers and thrombosis preventives or remedies comprising glucosamine
KR20050101143A (en) Methods and composition for the prevention and improvement of degenerative arthritis including glucosamin
JP5410152B2 (en) Anemia prevention composition
JP2009057336A (en) Wound-healing promoting composition comprising extract of momordica grosvenori and its application method
KR102482128B1 (en) Compositions containing new methylsulfonylmethane(MSM) with increased arthritis treatment effect and the process of manufacture thereof
RU2152221C1 (en) Agent with hepatoprotective, cholesterol and glucose content regulating effect
RU2414231C1 (en) Antioxidant
RU2122418C1 (en) Agent for treatment of patients with chronic hepatitis of an infectious etiology
KR20120068006A (en) Composition for lowering blood uric acid level

Legal Events

Date Code Title Description
WITN Withdrawal due to no request for examination